Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents - PubMed (original) (raw)
. 2011 Apr 14;54(7):2320-30.
doi: 10.1021/jm101488z. Epub 2011 Mar 17.
Steven J Durrant, Julian M C Golec, David P Kay, Ronald M A Knegtel, Somhairle MacCormick, Michael Mortimore, Michael E O'Donnell, Joanne L Pinder, Philip M Reaper, Alistair P Rutherford, Paul S H Wang, Stephen C Young, John R Pollard
Affiliations
- PMID: 21413798
- DOI: 10.1021/jm101488z
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents
Jean-Damien Charrier et al. J Med Chem. 2011.
Abstract
DNA-damaging agents are among the most frequently used anticancer drugs. However, they provide only modest benefit in most cancers. This may be attributed to a genome maintenance network, the DNA damage response (DDR), that recognizes and repairs damaged DNA. ATR is a major regulator of the DDR and an attractive anticancer target. Herein, we describe the discovery of a series of aminopyrazines with potent and selective ATR inhibition. Compound 45 inhibits ATR with a K(i) of 6 nM, shows >600-fold selectivity over related kinases ATM or DNA-PK, and blocks ATR signaling in cells with an IC(50) of 0.42 μM. Using this compound, we show that ATR inhibition markedly enhances death induced by DNA-damaging agents in certain cancers but not normal cells. This differential response between cancer and normal cells highlights the great potential for ATR inhibition as a novel mechanism to dramatically increase the efficacy of many established drugs and ionizing radiation.
Similar articles
- Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS, Perrin-Ninkovic SM, Harris R, Lee BG, Shevlin G, Hickman M, Khambatta G, Bisonette RR, Fultz KE, Sankar S. Mortensen DS, et al. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6793-9. doi: 10.1016/j.bmcl.2011.09.035. Epub 2011 Sep 16. Bioorg Med Chem Lett. 2011. PMID: 21978683 - Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL, Weinberg LR, Albom MS, Angeles TS, Cheng M, Ghose AK, Roemmele RC, Theroff JP, Underiner TL, Zificsak CA, Dorsey BD. Milkiewicz KL, et al. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. doi: 10.1016/j.bmc.2010.04.087. Epub 2010 Apr 29. Bioorg Med Chem. 2010. PMID: 20483621 - Sulfoximines as ATR inhibitors: Analogs of VE-821.
Hendriks CMM, Hartkamp J, Wiezorek S, Steinkamp AD, Rossetti G, Lüscher B, Bolm C. Hendriks CMM, et al. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2659-2662. doi: 10.1016/j.bmcl.2017.04.026. Epub 2017 Apr 8. Bioorg Med Chem Lett. 2017. PMID: 28479198 - Discovery and development of aurora kinase inhibitors as anticancer agents.
Pollard JR, Mortimore M. Pollard JR, et al. J Med Chem. 2009 May 14;52(9):2629-51. doi: 10.1021/jm8012129. J Med Chem. 2009. PMID: 19320489 Review. No abstract available. - Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W, Pytel D, Nowak-Zduńczyk A, Lewko D, Wojtczak R, Diehl JA, Majsterek I. Rozpędek W, et al. Curr Med Chem. 2019;26(8):1425-1445. doi: 10.2174/0929867325666180117102233. Curr Med Chem. 2019. PMID: 29345572 Review.
Cited by
- A sophisticated mechanism governs Pol ζ activity in response to replication stress.
Li C, Fan S, Li P, Bai Y, Wang Y, Cui Y, Li M, Wang R, Shao Y, Wang Y, Zheng S, Wang R, Gao L, Li M, Zheng Y, Wang F, Gao S, Feng S, Wang J, Qu X, Li X. Li C, et al. Nat Commun. 2024 Aug 31;15(1):7562. doi: 10.1038/s41467-024-52112-z. Nat Commun. 2024. PMID: 39215012 Free PMC article. - The effect of replication protein A inhibition and post-translational modification on ATR kinase signaling.
Jordan MR, Oakley GG, Mayo LD, Balakrishnan L, Turchi JJ. Jordan MR, et al. Sci Rep. 2024 Aug 26;14(1):19791. doi: 10.1038/s41598-024-70589-y. Sci Rep. 2024. PMID: 39187637 Free PMC article. - The Effect of Replication Protein A Inhibition and Post-Translational Modification on ATR Kinase Signaling.
Jordan MR, Oakley GG, Mayo LD, Balakrishnan L, Turchi JJ. Jordan MR, et al. Res Sq [Preprint]. 2024 Jul 26:rs.3.rs-4570504. doi: 10.21203/rs.3.rs-4570504/v1. Res Sq. 2024. PMID: 39108493 Free PMC article. Updated. Preprint. - Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC, Wang J, Rose KL, Jones C, Patel P, Tsui T, Florian AC, Vlach L, Lorey SL, Grieb BC, Smith BN, Slota MJ, Reynolds EM, Goswami S, Savona MR, Mason FM, Lee T, Fesik S, Liu Q, Tansey WP. Howard GC, et al. Elife. 2024 Apr 29;12:RP90683. doi: 10.7554/eLife.90683. Elife. 2024. PMID: 38682900 Free PMC article. - Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC, Wang J, Rose KL, Jones C, Patel P, Tsui T, Florian AC, Vlach L, Lorey SL, Grieb BC, Smith BN, Slota MJ, Reynolds EM, Goswami S, Savona MR, Mason FM, Lee T, Fesik SW, Liu Q, Tansey WP. Howard GC, et al. bioRxiv [Preprint]. 2024 Jan 10:2023.07.26.550648. doi: 10.1101/2023.07.26.550648. bioRxiv. 2024. PMID: 37546802 Free PMC article. Updated. Preprint.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials
Miscellaneous